A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Stopped New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study

Conditions

• Depressive Disorder, Treatment-Resistant

Interventions

• DRUG: Esketamine 28 mg
• DRUG: Esketamine 56 mg
• DRUG: Esketamine 84 mg
• DRUG: Placebo
• DRUG: Escitalopram
• DRUG: Sertraline
• DRUG: Duloxetine
• DRUG: Mirtazapine
• DRUG: Agomelatine
• DRUG: Bupropion
• DRUG: Trazodone Prolonged Release

Sponsor

Janssen-Cilag International NV